Child Kidney Dis.  2023 Dec;27(2):82-88. 10.3339/ckd.23.016.

Anemia in children with chronic kidney disease

• Park MJ
• Cho MH

• KMID: 2549738
• DOI: http://doi.org/10.3339/ckd.23.016

Abstract

Chronic kidney disease (CKD) causes numerous changes that destabilize homeostasis, of which anemia is one of its important complications. Anemia significantly reduces the quality of life in children with CKD and plays a crucial role in the progression of cardiovascular disease such as left ventricular hypertrophy, a major cause of mortality in those with advanced CKD. The treatment of anemia is a pivotal factor in reducing morbidity and mortality rates in children with CKD, representing one of the methods for enhancing patients’ quality of life.

Keyword

Anemia; Children; Chronic kidney disease

Reference

References

1. Bright R. Cases and observations illustrative of renal disease, accompanied with the secretion of albuminous urine. Med Chir Rev. 1836; 25:23–35.

2. Cameron JS. Sir Robert Christison (1797-1882): the man, his times, and his contributions to nephrology. J R Coll Physicians Edinb. 2007; 37:155–72.

3. Fadrowski JJ, Pierce CB, Cole SR, Moxey-Mims M, Warady BA, Furth SL. Hemoglobin decline in children with chronic kidney disease: baseline results from the chronic kidney disease in children prospective cohort study. Clin J Am Soc Nephrol. 2008; 3:457–62.

4. Atkinson MA, Martz K, Warady BA, Neu AM. Risk for anemia in pediatric chronic kidney disease patients: a report of NAPRTCS. Pediatr Nephrol. 2010; 25:1699–706.

5. KDOQI; National Kidney Foundation. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease. Am J Kidney Dis 2006;47:S11-145.

6. Gerson A, Hwang W, Fiorenza J, Barth K, Kaskel F, Weiss L, et al. Anemia and health-related quality of life in adolescents with chronic kidney disease. Am J Kidney Dis. 2004; 44:1017–23.

7. Baek HS, Kang HG, Choi HJ, Cheong HI, Ha IS, Han KH, et al. Health-related quality of life of children with pre-dialysis chronic kidney disease. Pediatr Nephrol. 2017; 32:2097–105.

8. Matteucci MC, Wuhl E, Picca S, Mastrostefano A, Rinelli G, Romano C, et al. Left ventricular geometry in children with mild to moderate chronic renal insufficiency. J Am Soc Nephrol. 2006; 17:218–26.

9. Mitsnefes MM. Cardiovascular disease in children with chronic kidney disease. J Am Soc Nephrol. 2012; 23:578–85.

10. Staples AO, Wong CS, Smith JM, Gipson DS, Filler G, Warady BA, et al. Anemia and risk of hospitalization in pediatric chronic kidney disease. Clin J Am Soc Nephrol. 2009; 4:48–56.

11. Amaral S, Hwang W, Fivush B, Neu A, Frankenfield D, Furth S. Association of mortality and hospitalization with achievement of adult hemoglobin targets in adolescents maintained on hemodialysis. J Am Soc Nephrol. 2006; 17:2878–85.

12. Warady BA, Ho M. Morbidity and mortality in children with anemia at initiation of dialysis. Pediatr Nephrol. 2003; 18:1055–62.

13. Jacobson LO, Goldwasser E, Fried W, Plzak L. Role of the kidney in erythropoiesis. Nature. 1957; 179:633–4.

14. Adamson JW, Eschbach J, Finch CA. The kidney and erythropoiesis. Am J Med. 1968; 44:725–33.

15. Babitt JL, Lin HY. Mechanisms of anemia in CKD. J Am Soc Nephrol. 2012; 23:1631–4.

16. Atkinson MA, Warady BA. Anemia in chronic kidney disease. Pediatr Nephrol. 2018; 33:227–38.

17. Atkinson MA, Furth SL. Anemia in children with chronic kidney disease. Nat Rev Nephrol. 2011; 7:635–41.

18. Koshy SM, Geary DF. Anemia in children with chronic kidney disease. Pediatr Nephrol. 2008; 23:209–19.

19. Babitt JL, Lin HY. Molecular mechanisms of hepcidin regulation: implications for the anemia of CKD. Am J Kidney Dis. 2010; 55:726–41.

20. Zaritsky J, Young B, Wang HJ, Westerman M, Olbina G, Nemeth E, et al. Hepcidin: a potential novel biomarker for iron status in chronic kidney disease. Clin J Am Soc Nephrol. 2009; 4:1051–6.

21. Ganz T, Nemeth E. Iron balance and the role of hepcidin in chronic kidney disease. Semin Nephrol. 2016; 36:87–93.

22. Atkinson MA, Kim JY, Roy CN, Warady BA, White CT, Furth SL. Hepcidin and risk of anemia in CKD: a cross-sectional and longitudinal analysis in the CKiD cohort. Pediatr Nephrol. 2015; 30:635–43.

23. Nemeth E, Ganz T. Hepcidin and iron in health and disease. Annu Rev Med. 2023; 74:261–77.

24. Atkinson MA, Pierce CB, Zack RM, Barletta GM, Yadin O, Mentser M, et al. Hemoglobin differences by race in children with CKD. Am J Kidney Dis. 2010; 55:1009–17.

25. Hollowell JG, van Assendelft OW, Gunter EW, Lewis BG, Najjar M, Pfeiffer C, et al. Hematological and iron-related analytes: reference data for persons aged 1 year and over: United States, 1988-94. Vital Health Stat 11. 2005; (247):1–156.

26. National Kidney Foundation Anemia Working Group. IV. NKF-K/DOQI clinical practice guidelines for anemia of chronic kidney disease: update 2000. Am J Kidney Dis. 2001; 37(1 Suppl 1):S182–238.

27. Filler G, Mylrea K, Feber J, Wong H. How to define anemia in children with chronic kidney disease? Pediatr Nephrol. 2007; 22:702–7.

28. McMurray J, Parfrey P, Adamson JW, Aljama P, Berns JS, Bohlius J, et al. Kidney Disease: Improving Global Outcomes (KDIGO) anemia work group: KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int Suppl. 2012; 279:702–335.

29. Eschbach JW, Abdulhadi MH, Browne JK, Delano BG, Downing MR, Egrie JC, et al. Recombinant human erythropoietin in anemic patients with end-stage renal disease: results of a phase III multicenter clinical trial. Ann Intern Med. 1989; 111:992–1000.

30. Canadian Erythropoietin Study Group. Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. BMJ. 1990; 300:573–8.

31. Nissenson AR, Swan SK, Lindberg JS, Soroka SD, Beatey R, Wang C, et al. Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients. Am J Kidney Dis. 2002; 40:110–8.

32. Levin NW, Fishbane S, Canedo FV, Zeig S, Nassar GM, Moran JE, et al. Intravenous methoxy polyethylene glycol-epoetin beta for haemoglobin control in patients with chronic kidney disease who are on dialysis: a randomised non-inferiority trial (MAXIMA). Lancet. 2007; 370:1415–21.

33. Krapf R, Hulter HN. Arterial hypertension induced by erythropoietin and erythropoiesis-stimulating agents (ESA). Clin J Am Soc Nephrol. 2009; 4:470–80.

34. McCullough PA, Barnhart HX, Inrig JK, Reddan D, Sapp S, Patel UD, et al. Cardiovascular toxicity of epoetin-alfa in patients with chronic kidney disease. Am J Nephrol. 2013; 37:549–58.

35. Smith KJ, Bleyer AJ, Little WC, Sane DC. The cardiovascular effects of erythropoietin. Cardiovasc Res. 2003; 59:538–48.

36. Horl WH. Anaemia management and mortality risk in chronic kidney disease. Nat Rev Nephrol. 2013; 9:291–301.

37. Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med. 1998; 339:584–90.

38. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006; 355:2085–98.

39. Parfrey PS, Foley RN, Wittreich BH, Sullivan DJ, Zagari MJ, Frei D. Double-blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart disease. J Am Soc Nephrol. 2005; 16:2180–9.

40. Palmer SC, Navaneethan SD, Craig JC, Johnson DW, Tonelli M, Garg AX, et al. Meta-analysis: erythropoiesis-stimulating agents in patients with chronic kidney disease. Ann Intern Med. 2010; 153:23–33.

41. Coyne DW. The health-related quality of life was not improved by targeting higher hemoglobin in the Normal Hematocrit Trial. Kidney Int. 2012; 82:235–41.

42. Johnson DW, Pollock CA, Macdougall IC. Erythropoiesis-stimulating agent hyporesponsiveness. Nephrology (Carlton). 2007; 12:321–30.

43. Kalantar-Zadeh K, Lee GH, Miller JE, Streja E, Jing J, Robertson JA, et al. Predictors of hyporesponsiveness to erythropoiesis-stimulating agents in hemodialysis patients. Am J Kidney Dis. 2009; 53:823–34.

44. Seeherunvong W, Rubio L, Abitbol CL, Montane B, Strauss J, Diaz R, et al. Identification of poor responders to erythropoietin among children undergoing hemodialysis. J Pediatr. 2001; 138:710–4.

45. Macdougall IC, Bircher AJ, Eckardt KU, Obrador GT, Pollock CA, Stenvinkel P, et al. Iron management in chronic kidney disease: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference. Kidney Int. 2016; 89:28–39.

46. Gillespie RS, Wolf FM. Intravenous iron therapy in pediatric hemodialysis patients: a meta-analysis. Pediatr Nephrol. 2004; 19:662–6.

47. Morgan HE, Gautam M, Geary DF. Maintenance intravenous iron therapy in pediatric hemodialysis patients. Pediatr Nephrol. 2001; 16:779–83.

48. Neu AM, Ho PL, McDonald RA, Warady BA. Chronic dialysis in children and adolescents. The 2001 NAPRTCS Annual Report. Pediatr Nephrol. 2002; 17:656–63.

49. Warady BA, Kausz A, Lerner G, Brewer ED, Chadha V, Brugnara C, et al. Iron therapy in the pediatric hemodialysis population. Pediatr Nephrol. 2004; 19:655–61.

50. Schroder CH; European Pediatric Peritoneal Dialysis Working Group. The management of anemia in pediatric peritoneal dialysis patients. Guidelines by an ad hoc European committee. Pediatr Nephrol. 2003; 18:805–9.

51. Van Damme-Lombaerts R, Herman J. Erythropoietin treatment in children with renal failure. Pediatr Nephrol. 1999; 13:148–52.

52. Bothwell TH, Pirzio-Biroli G, Finch CA. Iron absorption. I. Factors influencing absorption. J Lab Clin Med. 1958; 51:24–36.

53. Morgan HE, Holt RC, Jones CA, Judd BA. Intravenous iron treatment in paediatric chronic kidney disease patients not on erythropoietin. Pediatr Nephrol. 2007; 22:1963–5.

54. Yorgin PD, Belson A, Sarwal M, Alexander SR. Sodium ferric gluconate therapy in renal transplant and renal failure patients. Pediatr Nephrol. 2000; 15:171–5.

55. Horl WH. Iron therapy for renal anemia: how much needed, how much harmful? Pediatr Nephrol. 2007; 22:480–9.

56. Chandler G, Harchowal J, Macdougall IC. Intravenous iron sucrose: establishing a safe dose. Am J Kidney Dis. 2001; 38:988–91.

57. Haase VH. HIF-prolyl hydroxylases as therapeutic targets in erythropoiesis and iron metabolism. Hemodial Int. 2017; 21 Suppl 1(Suppl 1):S110–24.

58. Haase VH. Hypoxia-inducible factor-prolyl hydroxylase inhibitors in the treatment of anemia of chronic kidney disease. Kidney Int Suppl (2011). 2021; 11:8–25.

59. Locatelli F, Fishbane S, Block GA, Macdougall IC. Targeting hypoxia-inducible factors for the treatment of anemia in chronic kidney disease patients. Am J Nephrol. 2017; 45:187–99.

60. Singh AK, Carroll K, Perkovic V, Solomon S, Jha V, Johansen KL, et al. Daprodustat for the treatment of anemia in patients undergoing dialysis. N Engl J Med. 2021; 385:2325–35.

61. Akizawa T, Nangaku M, Yonekawa T, Okuda N, Kawamatsu S, Onoue T, et al. Efficacy and safety of daprodustat compared with darbepoetin alfa in Japanese hemodialysis patients with anemia: a randomized, double-blind, phase 3 trial. Clin J Am Soc Nephrol. 2020; 15:1155–65.

62. Singh AK, Carroll K, McMurray JJV, Solomon S, Jha V, Johansen KL, et al. Daprodustat for the treatment of anemia in patients not undergoing dialysis. N Engl J Med. 2021; 385:2313–24.

63. Zheng Q, Yang H, Sun L, Wei R, Fu X, Wang Y, et al. Efficacy and safety of HIF prolyl-hydroxylase inhibitor vs epoetin and darbepoetin for anemia in chronic kidney disease patients not undergoing dialysis: a network meta-analysis. Pharmacol Res. 2020; 159:105020.

64. Hiemstra T, Vick JG, Roberts JC. WCN23-0672 Daprodustat for treatment of anemia of CKD in pediatric patients: protocol for the ASCEND-P trial within a cohort. Kidney Int Rep. 2023; 8(3 Suppl):S150–1.

65. Shah HH, Fishbane S. Anemia and its treatment in patients with end-stage kidney disease. In : Nissenson AR, Fine RN, Mehrotra R, Zaritsky J, editors. Handbook of dialysis therapy. Elsevier;2023. p. 341–50.

66. Niaudet P, Dudley J, Charbit M, Gagnadoux MF, Macleay K, Broyer M. Pretransplant blood transfusions with cyclosporine in pediatric renal transplantation. Pediatr Nephrol. 2000; 14:451–6.